F-18 Labelled PSMA-1007: Biodistribution, Radiation Dosimetry and Histopathological Validation of Tumor Lesions in Prostate Cancer Patients

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2016 Nov 28

PMID 27889802

Citations 240

Authors

Frederik L Giesel

B Hadaschik

J Cardinale

J Radtke

M Vinsensia

W Lehnert

C Kesch

Y Tolstov

S Singer

N Grabe

S Duensing

M Schafer

O C Neels

W Mier

U Haberkorn

K Kopka

C Kratochwil

Affiliations

Soon will be listed here.

Abstract

Purpose: The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of F-labelled analogs. F-PSMA-1007 was selected among several F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake and fast, non-urinary background clearance. Here, we describe the properties of F-PSMA-1007 in human volunteers and patients.

Methods: Radiation dosimetry of F-PSMA-1007 was determined in three healthy volunteers who underwent whole-body PET-scans and concomitant blood and urine sampling. Following this, ten patients with high-risk prostate cancer underwent F-PSMA-1007 PET/CT (1 h and 3 h p.i.) and normal organ biodistribution and tumor uptakes were examined. Eight patients underwent prostatectomy with extended pelvic lymphadenectomy. Uptake in intra-prostatic lesions and lymph node metastases were correlated with final histopathology, including PSMA immunostaining.

Results: With an effective dose of approximately 4.4-5.5 mSv per 200-250 MBq examination, F-PSMA-1007 behaves similar to other PSMA-PET agents as well as to other F-labelled PET-tracers. In comparison to other PSMA-targeting PET-tracers, F-PSMA-1007 has reduced urinary clearance enabling excellent assessment of the prostate. Similar to F-DCFPyL and with slightly slower clearance kinetics than PSMA-11, favorable tumor-to-background ratios are observed 2-3 h after injection. In eight patients, diagnostic findings were successfully validated by histopathology. F-PSMA-1007 PET/CT detected 18 of 19 lymph node metastases in the pelvis, including nodes as small as 1 mm in diameter.

Conclusion: F-PSMA-1007 performs at least comparably to Ga-PSMA-11, but its longer half-life combined with its superior energy characteristics and non-urinary excretion overcomes some practical limitations of Ga-labelled PSMA-targeted tracers.

Citing Articles

Clinical comprehensive evaluation of [F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [F]FDG.

Zhang Z, Liu S, Liang S, Bai X, He Y, Zhong J Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40055208 DOI: 10.1007/s00259-025-07171-9.

Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.

Fang J, Alhaskawi A, Dong Y, Cheng C, Xu Z, Tian J J Zhejiang Univ Sci B. 2025; 26(2):124-144.

PMID: 40015933 PMC: 11867783. DOI: 10.1631/jzus.B2300614.

Role of F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study.

Fan J, Xu K, Jiang Z, Gan C, Song H, Gao G BMC Cancer. 2025; 25(1):192.

PMID: 39901140 PMC: 11789373. DOI: 10.1186/s12885-025-13482-9.

Impact of delayed pelvic imaging on the staging of biochemical recurrence in prostate cancer patients using [F]DCFPYL PET/CT: a retrospective evaluation.

Rodriguez-Pajuelo A, Guerra-Gomez M, Cuenca Cuenca J, Freire-Macias J, Jimenez-Hoyuela Garcia J, Alvarez-Perez R EJNMMI Rep. 2025; 9(1):5.

PMID: 39890711 PMC: 11785851. DOI: 10.1186/s41824-025-00238-8.

Investigating the significance of SPECT/CT-SUV for monitoring Lu-PSMA-targeted radionuclide therapy: a systematic review.

Alkahtani T BMC Med Imaging. 2025; 25(1):28.

PMID: 39875849 PMC: 11776189. DOI: 10.1186/s12880-025-01571-x.

References

Pfob C, Ziegler S, Graner F, Kohner M, Schachoff S, Blechert B . Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016; 43(11):1962-70. DOI: 10.1007/s00259-016-3424-3. View

Cardinale J, Schafer M, Benesova M, Bauder-Wust U, Leotta K, Eder M . Preclinical Evaluation of F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. J Nucl Med. 2016; 58(3):425-431. DOI: 10.2967/jnumed.116.181768. View

Vallabhajosula S, Nikolopoulou A, Babich J, Osborne J, Tagawa S, Lipai I . 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014; 55(11):1791-8. DOI: 10.2967/jnumed.114.140426. View

Sgouros G . Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993; 34(4):689-94. View

Cho S, Gage K, Mease R, Senthamizhchelvan S, Holt D, Jeffrey-Kwanisai A . Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012; 53(12):1883-91. PMC: 3742115. DOI: 10.2967/jnumed.112.104661. View

Shen S, Meredith R, Duan J, Macey D, Khazaeli M, Robert F . Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med. 2002; 43(9):1245-53. View

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

Budaus L, Leyh-Bannurah S, Salomon G, Michl U, Heinzer H, Huland H . Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol. 2015; 69(3):393-6. DOI: 10.1016/j.eururo.2015.06.010. View

Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel F, Hope T . Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016; 43(9):1611-20. DOI: 10.1007/s00259-016-3419-0. View

10.

Kratochwil C, Bruchertseifer F, Giesel F, Weis M, Verburg F, Mottaghy F . 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016; 57(12):1941-1944. DOI: 10.2967/jnumed.116.178673. View

11.

Olberg D, Arukwe J, Grace D, Hjelstuen O, Solbakken M, Kindberg G . One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18. J Med Chem. 2010; 53(4):1732-40. DOI: 10.1021/jm9015813. View

12.

Benesova M, Bauder-Wust U, Schafer M, Klika K, Mier W, Haberkorn U . Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem. 2016; 59(5):1761-75. DOI: 10.1021/acs.jmedchem.5b01210. View

13.

Szabo Z, Mena E, Rowe S, Plyku D, Nidal R, Eisenberger M . Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015; 17(4):565-74. PMC: 4531836. DOI: 10.1007/s11307-015-0850-8. View

14.

Fendler W, Schmidt D, Wenter V, Thierfelder K, Zach C, Stief C . 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. J Nucl Med. 2016; 57(11):1720-1725. DOI: 10.2967/jnumed.116.172627. View

15.

Andersson M, Johansson L, Minarik D, Mattsson S, Leide-Svegborn S . An internal radiation dosimetry computer program, IDAC 2.0, for estimation of patient doses from radiopharmaceuticals. Radiat Prot Dosimetry. 2013; 162(3):299-305. DOI: 10.1093/rpd/nct337. View

16.

Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff C . Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7(11):12477-88. PMC: 4914299. DOI: 10.18632/oncotarget.7245. View

17.

Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q . Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015; 56(8):1185-90. DOI: 10.2967/jnumed.115.160382. View

18.

. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2003; 32(3-4):5-265. View

19.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels O . The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med. 2015; 56(11):1697-705. DOI: 10.2967/jnumed.115.161299. View

20.

Afshar-Oromieh A, Avtzi E, Giesel F, Holland-Letz T, Linhart H, Eder M . The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 42(2):197-209. PMC: 4315487. DOI: 10.1007/s00259-014-2949-6. View